Antisense approaches in drug discovery and development.
Rayburn
Elizabeth
E
Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, VH 112, Box 600, 1670 University Blvd., Birmingham, AL 35294-0019, USA.
Wang
Wei
W
Zhang
Ruiwen
R
Wang
Hui
H
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D015195:Drug Design; D011905:Genes, ras; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000235:genetics; D000077022:Survivin; D013873:Thionucleotides / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D000077022:Survivin; D013873:Thionucleotides; D042461:Vascular Endothelial Growth Factor A; C408162:oblimersen; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C